US subsidiary recalls two products over quality issues
UNICHEMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Unichem Laboratories' US subsidiary, Unichem Pharmaceuticals (USA), is voluntarily recalling two products distributed in the US. Doxazosin Tablets (4 mg) is being recalled due to incorrect debossing on some tablets, and Bisoprolol Fumarate and Hydrochlorothiazide Tablets (2.5 mg/6.25 mg) is being recalled for not meeting N-Nitroso Bisoprolol impurity specification limits. No adverse events have been reported. The company has emphasised its focus on patient safety and product quality.
Short-term negative on US segment sentiment; recall costs and reputational risk remain. No adverse events reported so far may limit damage.